Point72 Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Point72 Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200,000	Closed	-$21.5M	–	2947
2023 Q1	$21.5M	Buy	+200,000	New	+$23M	0.07%	342

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Point72 Asset Management's RXDX Position: Q2 2023 in Review

Point72 Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,465,420 shares — an estimated $157M sold.

Point72 Asset Management first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $157M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Point72 Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Point72 Asset Management sold 1,465,420 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $157M.
Point72 Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Point72 Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $157M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.